948015-72-3

Usage

Uses

Used in Pharmaceutical Synthesis:
Tert-butyl 3-(cyanomethyl)piperidine-1-carboxylate is used as a building block for the development of new pharmaceuticals, leveraging its unique structure to contribute to the creation of novel drug candidates with potential therapeutic applications.
Used in Agrochemical Development:
In the agrochemical industry, tert-butyl 3-(cyanomethyl)piperidine-1-carboxylate serves as a key component in the synthesis of new agrochemicals, potentially enhancing crop protection and yield through innovative chemical formulations.
Used in Organic Chemistry Reactions:
Tert-butyl 3-(cyanomethyl)piperidine-1-carboxylate is utilized as a reagent in various organic chemistry reactions, where it can function as a protecting group or serve as a precursor to other valuable compounds, expanding the scope of synthetic organic chemistry.
Used in Fine Chemicals Production:
tert-Butyl 3-(cyanomethyl)piperidine-1-carboxylate is also employed in the production of fine chemicals, where its specific properties can be harnessed to create high-quality specialty chemicals for diverse applications.

Upstream product

• 4606-65-9 3-(hydroxymethy)piperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 116574-71-1 (±)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate 
• 98977-36-7 3-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 1159982-27-0 tert-butyl 3-(cyanomethylene)piperidine-1-carboxylate 
• 162166-99-6 3-methanesulfonyloxymethyl-piperidine-1-carboxylic acid tert-butyl ester 
• 191092-05-4 1-t-butoxycarbonyl-3-(p-toluenesulfonyloxymethyl)piperidine 
• 1159982-27-0 (E)-tert-butyl 3-(cyanomethylene)piperidin-1-carboxylate 
• 773837-37-9 sodium cyanide 

Downstream Products

• 5562-22-1 3-Cyanomethylpiperidine 
• 1083181-70-7 2-(1-benzylpiperidin-3-yl)ethan-1-amine 
• 372159-76-7 tert-butyl 3-(2-oxoethyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

NOVEL HISTONE METHYLTRANSFERASE INHIBITORS

The present invention relates to novel compounds of formula (I) as defined herein. The compounds are inhibitors of histone methyltransferases of the seven-beta-strand family, in particular of KMT9.

Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors

A series of tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors was designed and synthesized. Compounds were optimized in terms of potency, selectivity, and synthetic accessibility. The crystal structure of the inhibitor 18 in complex with BChE revealed the molecular basis for its low nanomolar inhibition (IC50 = 2.8 nM). The favourable in vitro results enabled a first-in-animal in vivo efficacy and safety trial, which demonstrated a positive impact on fear-motivated and spatial long-term memory retrieval without any concomitant adverse motor effects. Altogether, this research culminated in a handful of new lead compounds with promising potential for symptomatic treatment of patients with Alzheimer's disease.

FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE

A fused bicyclic compound having an effect in inhibition of the activity of a tyrosine kinase, and preparation and use thereof are disclosed. In particular, a compound of formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydr

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

The design and discovery of novel amide CCR5 antagonists

The synthesis of a range of novel amine-containing structures and their primary potency as inhibitors of HIV-1 fusion via blocking of the CCR5 receptor is described. The development of the medicinal chemistry strategy and SAR's which led to the identification of the piperidine amide compounds 33 and 36 as excellent leads for further evaluation is described, along with key physicochemical data which highlighted their lead potential.